Journal: Nature Communications
Article Title: SPNS2 exports sphingosine-1-phosphate and imports glucose
doi: 10.1038/s41467-026-71659-7
Figure Lengend Snippet: a ConSurf analysis of hSPNS2 protein. b Pairwise Alignment Scores for hSPNS2 protein and DNA sequences with putative homologs arranged according to the degree of sequence identity. c S1P levels in blood (n = 13, 15), lymph fluid (n = 10, 12), perfused liver, lung, kidney, heart (n = 3, 3). d Glucose levels in blood (n = 10,14), lymph fluid (n = 7, 13), perfused liver (n = 7, 5), lung (n = 7, 10), kidney (n = 5, 5), heart (n = 5, 5). e Glucose levels in urine (n = 7, 6), feces (n = 10, 8), tibialis anterior muscle (n = 5, 5), and gonadal adipose tissue (n = 4, 5). f Body weights (n = 20, 20). Body composition expressed as percentage of fat mass (n = 12, 12). g Food consumption, energy balance, energy expenditure, and locomotor activity (Beam breaks/h) determined with the PhenoMaster (n = 9,10; N = 3). h Blood hemoglobin concentration (n = 17, 9) and percentage of glycosylated hemoglobin, HbA1c (n = 7, 7). i Oral glucose tolerance test (GTT) and area under the curve (AUC) (n = 5, 5; N = 2). j Plasma levels of fasting insulin (n = 14, 14), glucagon (n = 8, 8) and thyroid hormone triiodothyronine (T3). Data are means ± s.e.m. k – n PET-CT imaging analysis of 2-FDG in Spns2 –/– mice. PET tracer 2-FDG (270–550 µCi) was gavaged prior to anesthetization of WT or Spns2 –/– mice for PET-CT scans. (n = 3, 3, N = 2). k , l At 60 min, tracer activity of target organs was quantified in volumes of interest (VOI). Data are percentage of whole-body activity for the right kidney (RK), heart, and bladder (Bl). l Coronal sections (0.4 mm thick) of PET images are presented according to a spectral scale for tracer activity, from red (highest), to green (intermediate), to blue (lowest). m The distribution of 2-FDG in representative WT at the specified times following gavage is shown to demonstrate the assessment of gastric emptying and intestinal absorption. St, stomach; In, intestines. n Representative images of the VOI in bladder to determine % of urinary excretion. o % of urinary excretion, gastric emptying and intestinal absorption. Data are means ± s.d. Two-tailed unpaired t-test. Source data are available for this figure in the Source Data file.
Article Snippet: Cells were seeded (200,000 cells/6-well) and 24 h later, the cell culture medium was replaced with glucose-free DMEM (Gibco, # A14430-01, phenol-red and glucose-free) with 10% FBS, 1 mM sodium pyruvate, and 1 × GlutaMax for 4 h. The medium was then replaced by DMEM without or with 1 g/L or 4.5 g/L glucose (#G8644, Sigma) for 24 h. In other experiments, cells were treated with 200 μM of the S1P lyase inhibitor A6770 (#29972, Cayman Chemical Company), 2 μM of the SPNS2 inhibitor SLF1081851 (#HY-149004, MedChemExpress), or the corresponding vehicles in medium with 4.5 g/L glucose for 24 h. Where indicated, cells were treated with 500 nM or 10 μM S1P (#860492, Avanti Polar Lipids) for 30 min, 100 nM insulin (#C-52310, PromoCell) for 4 h, 10 nM BAY-876 (#HY-100017, MedChemExpress) for 4 h, or with 1 μM LB-100 (#HY-18597, MedChemExpress), 10 μM DT-061 (#HY-112929, MedChemExpress), 2 nM Calyculin A (#HY-18983, MedChemExpress), or 100 nM Endothall (#HY-113976A, MedChemExpress) for 24 h in medium with 4.5 g/L glucose.
Techniques: Sequencing, Activity Assay, Concentration Assay, Clinical Proteomics, Positron Emission Tomography-Computed Tomography, Imaging, Two Tailed Test